Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
OwnerMargaret A. Shipp, Przemyslaw Juszczynski +4inventors
InventorsMargaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
Life of this patent
Estimating the term…
Abstract
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
Claims27
A method for detecting the presence of a Gal1 polypeptide or fragment thereof;
- or a Gal1 polynucleotide or fragment thereof in a sample comprising:
- a) contacting the sample with a compound which selectively binds to a Gal1 polypeptide or fragment thereof, optionally wherein the compound is an antibody, an antibody derivative, or an antibody fragment;
- or a nucleic acid probe or primer which selectively hybridizes to a Gal1 polynucleotide or fragment thereof, and is contacted with a nucleic acid probe, optionally wherein the sample comprises a transcribed polynucleotide, or a portion thereof;
- and
- b) determining whether the compound binds to a Gal1 polypeptide or fragment thereof in the sample to thereby detect the presence of a Gal1 polypeptide or fragment thereof;
- or determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a Gal1 polynucleotide or fragment thereof;
- optionally wherein the transcribed polynucleotide is mRNA or cDNA;
- optionally wherein the step of detecting further comprises amplifying the transcribed polynucleotide;
- optionally wherein the level of expression of Gal1 is assessed by detecting the presence in the sample of a transcribed polynucleotide which anneals with a Gal1 polynucleotide or anneals with a portion of a Gal1 polynucleotide, under stringent hybridization conditions.
2-4. (canceled)
A method for identifying a compound which binds to a Gal1 polypeptide or fragment thereof comprising:
- a) contacting a Gal1 polypeptide or fragment thereof, or a cell expressing said polypeptide with a test compound;
- and
- b) determining whether said polypeptide binds to the test compound.
(canceled)
11-19. (canceled)
(canceled)
(canceled)
An isolated antibody or antigen binding portion thereof that specifically binds to a polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising the amino acid sequence of human Gal1;
- b) a polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence which is at least 80% homologous to a nucleic acid comprising the nucleotide sequence of human Gal1;
- and
- c) a polypeptide comprising an amino acid sequence which is at least 80% homologous to the amino acid sequence of human Gal1;
- optionally wherein the antibody or antigen binding portion thereof is a monoclonal antibody, a polyclonal antibody, a chimeric antibody, or a humanized antibody;
- optionally wherein the antibody or antigen binding portion thereof comprises an effector domain;
- optionally wherein the antibody or antigen binding portion thereof comprises an Fc domain;
- optionally wherein the antibody or antigen binding portion thereof is a single-chain antibody;
- and/or optionally wherein the antibody or antigen binding portion thereof is a Fab fragment.
31-33. (canceled)
37-42. (canceled)
Dependencies are inferred from the claim text.